Reata's Bardoxolone to treat a variety of rare kidney diseases is an activator of Nrf2. You know what else has recently been reported to be an activator of Nrf2 via increased transcription of Nrf2? The pan BET inhibitor JQ1. It would be extremely interesting if apabetalone (bromodomain-2 selective BET inhibitor) also increased the levels of Nrf2.

Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation

BearDownAZ